Back to results
US 2025/0025585 A1Published application
Her2 affibody radionuclide marker composition and application thereof
AssigneeJiangsu Yuanben Biotechnology Co., Ltd.
InventorsJiong CAI, Yi LIU, Dalin GAO, Xu SONG, Kai XIAO, Chen LIANG, Guozhong DING, Mingxia LIU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the fields of radiopharmaceuticals and nuclear medicine and provides a precursor composition of HER2 affibody, comprising: HEPES, sodium glucoheptonate, stannons chloride and an HER2 affibody, wherein the composition is free of vitamin C and cysteine, and the composition is a lyophilized powder.
Claims12
A precursor composition of HER2 affibody, comprising:
- HEPES, sodium glucoheptonate, stannous chloride and an HER2 affibody, wherein the composition is free of vitamin C and cysteine, and the composition is a lyophilized powder;
- preferably, in the composition, a molar ratio of HEPES:
- sodium glucoheptonate:
- stannous chloride:
- HER2 affibody is 2-30:5-40:0.1-5:0.01-0.6, further preferably 5-20:10-30:0.2-2:0.03-0.3, and most preferably 10:20:0.4:0.05.
2 more elements
A truncated HER2 affibody having the amino acid sequence as set forth in SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.